One of the scientists using Sercon’s ABCA2 at Southampton General Hospital is hopeful the technique he has developed will help in the prevention of liver damage and type 2 diabetes in a world where obesity is causing ever more health problems.

Dr Paul Afolabi, who works in the hospital’s medical research department, has been using the ABCA2 to detect the early stages of liver damage caused by fat build up. The patient drinks a sugary drink with a 13C enrichment, which is perfectly harmless, and then breathes into a tube a few times over the next hour. The tube is connected to an IRMS, where the 13C signal in the CO2 of the patient’s breath is monitored. This simple non-invasive breath test picks up liver damage at a very early early stage, before irreversible damage has occurred and other conditions such as type 2 diabetes have resulted from excess fat in the the patient.

Dr Afolabi is hoping the technique will aid physicians in diagnosing liver damage. For more information about this technique and other applications of the ABCA2, contact info@sercon.co.uk.

Would you like to learn more?

Contact our sales team.

International Sales?

Find your sales agent here.

C O L L A B O R A T E C R E A T E I N N O V A T E

Sercon Limited
Unit 3B Crewe Trade Park, Gateway, Crewe, Cheshire CW1 6JT
info@sercongroup.com
Tel: +44 (0) 1270 580008
Fax: +44 (0) 1270 252310
ISO 9001 AND ISO 13485+UKAS-CMYK
Copyright © 2019 Sercon Group.